Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Ascending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
S0182 Procarbazine Matulane 50 mg Chemotherapy Alkylating Agent Benzamide Yes 1969 Jan. 1, 2002 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
Q0167 Dronabinol Marinol 2.5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 April 1, 1998 In Use
Q0168 Dronabinol Marinol 5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 April 1, 1998 In Use
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct. 1, 2019 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 April 1, 2021 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan. 1, 2019 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use

Found 700 results in 1 millisecond — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.